General Information of Drug (ID: DMT4Z5B)

Drug Name
CALAA-01 Drug Info
Synonyms Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMT4Z5B

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Transferrin (TF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
EP-2167 DMERKYO Solid tumour/cancer 2A00-2F9Z Preclinical [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gemcitabine DMSE3I7 Anterior urethra cancer Approved [4]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [4]
CO-101 DMH5GQU Pancreatic cancer 2C10 Phase 2 [5]
Triapine DM7XZY5 Nerve injury ND56.4 Phase 2 [6]
LY-2334737 DMCBV20 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Gallium maltolate DMX0Z51 Human immunodeficiency virus infection 1C62 Discontinued in Phase 2 [8]
MDL 101,731 DMKEYSX Gastric adenocarcinoma 2B72 Discontinued in Phase 2 [9]
NKP-46 DMK8UD0 Solid tumour/cancer 2A00-2F9Z Preclinical [10]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ribonucleoside-diphosphate reductase M2 (RRM2) TTBWDI0 RIR2_HUMAN Modulator [2]
Transferrin (TF) TTV5YEH TRFE_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00689065) Safety Study of CALAA-01 to Treat Solid Tumor Cancers. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017941)
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
6 PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
7 Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
8 Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43.
9 Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40.
10 Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205.